Basic Prochlorperazine Information

• INN (International Nonproprietary Name): Prochlorperazine.
• Brand Names Available In Canada (English): Compazine has been cited historically in Canada and generics are broadly available.
• ATC Code: N05AB04.
• Forms & Dosages: Tablets 5 mg and 10 mg are the common community strengths.
• Forms & Dosages: Suppositories 25 mg are available in some markets but supply in Canadian community pharmacies varies.
• Forms & Dosages: Injectable ampoules/vials for IM/IV hospital use are available as 5 mg/mL and 12.5 mg/mL.
• Forms & Dosages: Oral solution or syrup listed as 5 mg/5 mL in international listings.
• Manufacturers In Canada (English): Generics supplied by manufacturers such as Heritage Pharmaceuticals, Teva, Sandoz and Fresenius Kabi are commonly cited.
• Registration Status In Canada (English): Registered as a prescription-only medicine in major jurisdictions; specific product DINs and current brand registrations should be checked in Health Canada databases or product monographs as they are not specified here.
• OTC / Rx Classification: Prescription Only (Rx) in major jurisdictions.
• Standard Dosages Per Condition: Severe nausea/vomiting — 5–10 mg orally three to four times daily or 5–10 mg IM/IV one to two times daily.
• Standard Dosages Per Condition: Schizophrenia/psychosis — initial 5–10 mg three to four times daily, titrated as needed (some sources list much higher specialist-guided maxima).
• Standard Dosages Per Condition: Pediatric dosing is weight-based and example dosing listed is approximately 0.13 mg/kg every 6–8 hours; consult official labelling for age-specific guidance.
• Population Dosing Adjustments: Use lower doses in children, elderly and in hepatic or renal impairment; avoid routine use in children under 2 years or under 10 kg without specialist approval.
• Typical Treatment Durations: Nausea/vomiting courses are usually short, often under seven days; psychiatric use requires specialist monitoring and regular review.
• Missed Dose Instructions: If a dose is missed, take as soon as remembered unless close to the next dose; do not double doses.
• Overdose Management: Supportive care is the mainstay; signs include CNS depression, respiratory depression, hypotension and extrapyramidal effects.
• Storage & Transport Guidelines: Store at room temperature (about 15–30°C) and protect from excessive moisture and light; injectable forms require specific handling instructions.
• Absolute Contraindications: Known hypersensitivity to prochlorperazine or phenothiazines, comatose patients, severe CNS depression, children under 2 years or under 10 kg (oral) and known bone marrow depression.
• Common Side Effects: Drowsiness, dizziness, blurred vision, dry mouth, constipation, hypotension, photosensitivity, weight gain and extrapyramidal symptoms such as tremor, restlessness and dystonia.

Latest Research Highlights

Patients ask: "How well does prochlorperazine actually work for sudden severe nausea?"

Recent literature reviews and international guidelines continue to recognise prochlorperazine as an effective phenothiazine antiemetic for acute severe nausea and vomiting.

Large-scale Canadian randomised controlled trials since 2022 are limited, and most Canadian practice relies on historical trials together with international systematic reviews and emergency department observational series up to 2023.

Regulatory positions in major agencies have been stable and generics remain widely available.

Meta-analyses comparing phenothiazines to ondansetron and haloperidol show comparable antiemetic control for many non-chemotherapy causes of nausea, but note a higher risk of extrapyramidal symptoms with phenothiazines.

Canadian clinicians balance efficacy against adverse effects in settings that favour conservative prescribing and universal coverage.

Rural hospitals commonly rely on parenteral formulations when oral intake is poor or vomiting prevents tablets from being absorbed.

Below is a concise table summarising trial outcomes and adverse-event reporting where available from reviews and ED series; specific numeric rates are not universally reported and are therefore noted as not specified where absent.

Clinical Effectiveness In Canada

People often want to know whether Canadian hospitals still use prochlorperazine and why.

Clinical effectiveness is well documented in older placebo-controlled trials showing fewer vomiting episodes with prochlorperazine for acute severe nausea.

Contemporary Canadian evidence is mostly guideline endorsements and hospital formulary policies rather than new RCTs.

International practice supports parenteral use in emergency departments and inpatient wards when quick control of vomiting is needed.

The ATC classification N05AB04 reflects both antipsychotic and antiemetic activity.

Health Canada-classified products remain prescription-only and multiple generics and brand formulations are available; specific DINs should be confirmed in product monographs.

Provincial formularies such as Ontario Drug Benefit, BC PharmaCare and RAMQ list antiemetics with variable coverage depending on indication and formulation.

Major pharmacy chains commonly stock tablets while injectables are typically hospital supplies and suppository availability varies.

Monitoring parameters commonly used in Canadian practice include blood pressure, level of sedation and early signs of extrapyramidal symptoms.

• Monitoring Parameter: Blood pressure and orthostatic symptoms.
• Monitoring Parameter: Level of sedation and fall risk, especially in seniors.
• Monitoring Parameter: Early extrapyramidal signs — dystonia, akathisia, tremor.
• Monitoring Parameter: Review of concurrent medications, seizure history and cardiac risk.

Indications And Expanded Uses

Patients ask: "What is this drug officially for, and when do doctors use it off-label?"

Primary evidence supports prochlorperazine for severe nausea and vomiting and as an antipsychotic for psychosis.

Short-term use for non-psychotic anxiety appears in older literature but is less common in current practice.

Off-label uses reported internationally include refractory migraine-associated nausea and symptom control in palliative care settings, though robust RCT data for these specific uses are limited.

Health Canada-approved indications typically reflect antiemetic and psychotropic uses, but exact authorised wording varies by product monograph and DIN.

In Canadian emergency care, clinicians commonly use prochlorperazine off-label for intractable nausea when ondansetron or metoclopramide are unsuitable or unavailable.

• Approved Uses: Severe nausea and vomiting; psychotic disorders (check product monograph for exact wording).
• Common Off-Label Uses: Migraine-related nausea, palliative symptom control, short-term acute anxiety in select settings.

When counselling patients, emphasise that nausea treatment with prochlorperazine is usually intended as a short course and that alternatives such as ondansetron and metoclopramide are available depending on indication and tolerance.

Composition And Brand Landscape

People search for brand names and whether generics are the same quality.

The active ingredient in all preparations is prochlorperazine, a phenothiazine-class compound.

Brand names cited in international listings include Compazine, Compro and Stemetil, with many generic manufacturers supplying tablets, injectables and suppositories.

In Canada, generics from large suppliers are commonly stocked and Compazine has been discontinued in some countries though historical listings include it in Canada.

Packaging must meet bilingual labelling requirements in Canada and cost-conscious patients frequently select generics.

Manufacturers supplying generics internationally and to Canadian markets include Heritage Pharmaceuticals, Teva, Sandoz, Fresenius Kabi and Medochemie.

Contraindications And Special Precautions

Many readers worry about serious risks and whether this drug is safe for a parent or grandparent.

Absolute contraindications include known hypersensitivity to prochlorperazine or other phenothiazines, comatose states or severe central nervous system depression, children under two years or under 10 kg for oral use, and known bone marrow depression.

Relative contraindications that demand caution include elderly patients, Parkinson’s disease, severe liver or kidney impairment, epilepsy and severe cardiovascular disease.

Elderly patients and those with dementia have a regulatory warning about increased mortality with antipsychotic use and require careful documented risk–benefit discussion.

Patients with seizure disorders need dose caution because prochlorperazine can lower the seizure threshold.

In rural and remote settings, where rapid specialist support is less accessible, clinicians often adopt dose-sparing strategies and closer monitoring.

• Absolute Contraindications: Hypersensitivity, comatose state, severe CNS depression, children under 2 years or <10 kg (oral), bone marrow depression.
• Relative Contraindications: Elderly with dementia, Parkinson’s disease, severe hepatic/renal disease, epilepsy, cardiovascular disease.

Elderly/Dementia Warning: Use the lowest effective dose and document the clinical justification when prescribing to older adults, and monitor for sedation, falls and extrapyramidal symptoms.

Dosage Guidelines

Common questions: "How much should I take and what if I am older or a child?"

For acute severe nausea the usual adult oral dose is 5–10 mg three to four times daily.

Parenteral dosing for IM/IV use is commonly 5–10 mg once or twice daily in hospital settings.

For psychotic disorders, initial adult dosing often starts at 5–10 mg three to four times daily with specialist titration and monitoring; some sources report much higher specialist-managed maxima.

Pediatric dosing is weight-based; an example guide lists approximately 0.13 mg/kg every 6–8 hours but precise age-based dosing must follow product labelling.

Reduce doses in elderly patients and in those with liver or kidney impairment and monitor closely.

When a dose is missed, take it when remembered unless the next dose is due soon; do not double up.

Interactions Overview

Patients often ask whether prochlorperazine is safe with their other medicines or alcohol.

Significant interactions include additive central nervous system depression with opioids, benzodiazepines and alcohol.

Concurrent dopamine antagonists increase extrapyramidal risk, and agents that prolong QTc, including some antiarrhythmics and antipsychotics, may interact in a clinically meaningful way.

Health Canada product monographs list many interacting agents and clinicians should perform a medication reconciliation prior to prescribing.

Alcohol potentiates sedation and orthostatic hypotension and should be avoided while taking this medicine.

Smoking alters metabolism of some psychotropics, though direct clinically important effects on prochlorperazine are not prominent in the available data.

Practical steps include pharmacist-led reconciliation in community and hospital settings and phone-based support for rural clinicians when complex interactions arise.

Cultural Perceptions And Patient Habits

People frequently report mixed experiences online: fast relief for nausea but worries about sleepiness and movement side effects.

Patient forums and Canadian clinician reports commonly compare prochlorperazine with ondansetron and metoclopramide, noting differences in tolerability and cost.

Canadians often prioritise low out-of-pocket cost and bilingual information when choosing medicines.

Indigenous communities may face culturally specific barriers such as continuity of care and limited local stock, which can affect uptake and adherence.

Rural patients may accept suppositories or injectables when oral therapy fails, but stigma around injectable antipsychotics can influence willingness to use certain formulations.

Community pharmacists provide leaflets in English and French and remain a primary source of counselling and troubleshooting for side effects.

Forum-reported side effects tend to emphasise sedation and dystonia, which aligns qualitatively with clinical trial safety signals such as drowsiness and extrapyramidal effects, though reported frequencies differ between anecdotes and formal studies.

Availability And Pricing Patterns

Access and cost are top-of-mind for many Canadians considering an anti-nausea medicine.

Generics ensure broad availability of tablets in community pharmacies, while injectables are usually hospital-supplied and suppositories are less consistently stocked.

Provincial drug plans influence out-of-pocket costs and many generics are covered on formularies, sometimes with special-authority requirements for chronic use.

Online Canadian pharmacies that verify prescriptions can supply prescription medicines with delivery across the country.

In our online pharmacy, prochlorperazine is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross-border purchasing from the United States may be cheaper for some patients but carries regulatory and formulation differences; the Compazine brand has been discontinued in some US regions and generics predominate.

Rural patients should plan for possible delays or temporary substitutions during stock-outs and consult their pharmacist about coverage through ODB, BC PharmaCare or RAMQ.

Comparable Medicines And Preferences

Common alternatives include metoclopramide, ondansetron, haloperidol and promethazine.

Ondansetron tends to be preferred in chemotherapy- and postoperative-induced nausea because of better tolerability and a lower extrapyramidal risk profile.

Phenothiazines such as prochlorperazine are effective and cost-efficient for many non-chemotherapy indications but come with a higher risk of dystonia and akathisia.

Metoclopramide provides prokinetic benefit useful in gastroparesis-related nausea but carries a tardive dyskinesia risk with longer-term use.

In Canadian practice the choice depends on indication, formulary coverage, side-effect profile and the patient’s comorbidities.

FAQ Section

• Q: Is prochlorperazine safe for seniors?

  A: Use the lowest effective dose and monitor for sedation, orthostatic hypotension and extrapyramidal symptoms.

  A: Many provincial plans cover short courses but check the specific formulary and DIN-based listings.

• Q: Can I drive while taking it?

  A: Avoid driving until you know how the medicine affects you because sedation and dizziness are common.

• Q: What if I am pregnant or breastfeeding?

  A: Discuss with your prescriber; product monographs and obstetrical guidance should be consulted to weigh risks and benefits.

• Q: Is it covered under my provincial plan?

  A: Coverage varies across ODB, BC PharmaCare and RAMQ; ask your pharmacist for DIN-based coverage details.

• Q: What if I miss a dose?

  A: Take the missed dose as soon as you remember unless the next dose is near; do not double doses.

For local formulary lookups, ask a pharmacist or consult provincial formulary websites using the product’s DIN.

Guidelines For Proper Use

Patients want clear, practical instructions they can follow at home.

Prescribe the lowest effective dose for the shortest effective duration for nausea, typically under seven days.

Specialist oversight and regular review are required for psychiatric indications and long-term use.

Monitor patients for extrapyramidal symptoms and cardiovascular effects, and instruct caregivers to report dystonia or severe restlessness immediately.

Community pharmacists should confirm indication, perform medication reconciliation and advise on bilingual counselling and side-effect management.

• Provide bilingual written instructions and a side-effect handout.
• Warn about sedation, orthostatic hypotension and signs of dystonia.
• Advise patients to avoid alcohol and to check with the pharmacist about interactions with opioids or benzodiazepines.
• Make a clear plan for persistent symptoms: return to the emergency department or contact your prescriber.

Delivery Across Canada (English)